Evidence map›Paper›PMID 35821184›Full record

ReviewEndocrine2022

Different treatment strategies in primary hyperparathyroidism during pregnancy.

A Eremkina, E Bibik, S Mirnaya, J Krupinova, A Gorbacheva, E Dobreva, N Mokrysheva

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Approach to the Patient: Management of Parathyroid Diseases Across Pregnancy.The Journal of clinical endocrinology and metabolism · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

A EremkinaEndocrinology Research Centre, Moscow, Russia.ORCID 0000-0001-6667-062X
E BibikEndocrinology Research Centre, Moscow, Russia. bibikaterina@mail.ru.ORCID 0000-0001-5952-5846
S MirnayaClinical Hospital on Yauza, Moscow, Russia.ORCID 0000-0002-1341-0397
J KrupinovaEndocrinology Research Centre, Moscow, Russia.ORCID 0000-0001-7963-5022
A GorbachevaEndocrinology Research Centre, Moscow, Russia.ORCID 0000-0001-6581-4521
E DobrevaEndocrinology Research Centre, Moscow, Russia.ORCID 0000-0002-8916-7346
N MokryshevaEndocrinology Research Centre, Moscow, Russia.ORCID 0000-0002-9717-9742
Endocrinology Research Center · RUClinical Hospital No. 8 · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrimary hyperparathyroidism (PHPT) in pregnancy is rare enough and can be unrecognized because of nonspecific symptoms in most cases, but life-threatening complications for mother, fetus and neonate also occurs. PHPT requires frequent monitoring of the mother and fetus by a multidisciplinary team. Diagnostics and treatment approaches are limited and require individual risk-benefit assessment.

methodsIn this paper we describe 3 cases of PHPT in pregnant women with different managing approaches (surveillance, drug therapy and surgical treatment) and successful outcomes. Additionally, the most actual literature data on this problem is reviewed.

resultsThe management of PHPT in pregnancy should be based on the clinical features, severity of hypercalcemia, gestational age and patient's preference. In the first case a conservative approach with low-calcium diet and oral hydration resulted in mother's reduced serum calcium level before delivery. The second patient had severe hypercalcemia and absolute indications for surgery that was successfully performed at 25 week of gestation. The third woman received cinacalcet because of severe hypercalcemia and potential perioperative risks in the third trimester with an improvement in well-being.

conclusionNowadays parathyroidectomy is the best choice for patients with symptomatic PHPT and severe hypercalcemia. This intervention should be carried out preferably in the second trimester to avoid maternal and fetal complications. Mild forms of the disease can require just a conservative management. The drug treatment of PHPT during pregnancy is still controversial.

Indexed as

HypercalcemiaHyperparathyroidism, PrimaryPregnancy ComplicationsCalciumCinacalcetFemaleHumansInfant, NewbornParathyroidectomyPregnancyCalciumCinacalcetCinacalcetHypercalcemiaParathyroid adenomaPregnancyPrimary hyperparathyroidism

Identifiers

PMID35821184
OpenAlexW4285090519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.